Morinaga Milk Reveals Major Breakthroughs in a ‘Bifidobacteria Training’ Program With Professional Footballer Yuto Nagatomo
31.8.2021 20:52:00 EEST | Business Wire | Press release
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a pioneer in bifidobacteria and gut microbiota research, reveals that its collaborative ‘Bifidobacteria Training’ project (launched in June 2020) helped professional athlete Yuto Nagatomo improve his gut microbiota. Nagatomo stayed on the program for a full year, and has been outspoken about the changes in his gut microbiota that not only improved his digestive system, but also his physical condition.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210831005058/en/
In recent crosstalk, footballer Yuto Nagatomo speaks passionately about his full year on the ‘Bifidobacteria Training’ program. “My condition improved because I stayed with it.” “Bifidobacteria ‘saved me’”, he shared. (Graphic: Business Wire)
About the ‘Bifidobacteria Training’ program
The program encourages participants to incorporate bifidobacteria into their existing knowledge, diet, and physical and mental health regimens with the aim of improving the environment of the large intestine through input from inside and outside the body.
The ‘Bifidobacteria Training’ program website offers a wealth of information not available elsewhere, including varied content on knowledge, diet, exercise, and mental health, and a profile of Yuto Nagatomo’s gut microbiota shaped by his consistent intake of bifidobacteria since 2020.
1. Overview of Report on ‘Bifidobacteria Training’ CROSS-TALK 2020-2021
Footballer Yuto Nagatomo started taking bifidobacteria in July 2020, during the offseason. He later signed with a French (Ligue 1) team, and his condition suffered as he attempted to adapt to an unfamiliar living environment. However, his digestive system steadily regained its balance thanks to his persistence with the ‘Bifidobacteria Training’ program. Our analysis of his gut microbiota revealed inconsistency immediately after his move to France, followed by certain changes that suggested a strong connection between his enteric bacteria and his physical condition.
Nagatomo recognized the changes as they were occurring. “My condition improved because I stayed with the ‘Bifidobacteria Training’ program every day,” he said. “Even on days I couldn’t sleep, both my digestive system and my physical condition were stable.” He also noted that his recovery speed had improved, and identified the source without uncertainty. “[Bifidobacteria] saved me.” His condition and performance on the field continuously improved. “I’m so much more confident now that I have the final piece of the puzzle in my goal to represent Japan in the 2022 World Cup.”
He reflected on his full year on the ‘Bifidobacteria Training’ program, noting that staying with it was important, yet not all that burdensome. “[Staying with the program] was everything for my gut microbiota,” he said in a nod to a Japanese adage about the value of persistence in sport. “It helped me so much. I’m grateful for the support.”
2. Changes in Yuto Nagatomo’s gut microbiota on the ‘Bifidobacteria Training’ program
Dr. Toshitaka Odamaki, Manager of the Microbiota Research Department at the Next Generation Science Institute of Morinaga Milk, analyzed Nagatomo’s gut microbiota over the roughly seven months in which he took bifidobacteria. “The balance of enteric bacteria shifted substantially after [Nagatomo] moved from Japan to France, but his intake of bifidobacteria and balanced meals created a new balance that stabilized in December,” Dr. Odamaki said, also confirming the disappearance of the harmful bacteria may be associated with the cause of Nagatomo’s illnesses. “The analysis showed increases in good bacteria such as bifidobacteria and butyrate-producing bacteria following his persistence with the ‘Bifidobacteria Training’ program.” Dr. Odamaki also noted that Nagatomo had a growing population of bacteria that is linked to the performance of professional athletes.” The changes in gut microbiota could be a factor behind Nagatomo’s sense that his condition improved.”
“This is the first experience to track the detailed changes in an individual’s gut microbial composition,” Dr. Odamaki said. “Our analysis illustrated a strong connection between tangible feelings and enteric bacteria, which are normally hidden from us, a significant finding among Morinaga Milk’s research.”
About professional footballer Yuto Nagatomo
Born in Ehime Prefecture, Japan in 1986. Made his official J. League debut with FC Tokyo in 2008. Invited to play on the Japanese national team for the first time in May 2008, and appeared in the Beijing Olympics in August of that year. Played every minute of Japan’s four games in the 2010 World Cup in South Africa, signed with Cesena of Serie A (Italy) in July of that year. Signed with the vaunted Inter Milan in January 2011. Played every minute of Japan’s games in the 2014 World Cup in Brazil. Joined Galatasaray S.K. of the TFF 1. Lig (Turkey) on loan in 2018. Advanced to the finals for the first time at the 2018 World Cup in Russia. Joined Galatasaray S.K. on a permanent deal in 2019, and won two consecutive Süper Lig titles and two Turkish Cup trophies. Signed with Olympique de Marseilles of Ligue 1 (France) on August 31, 2020. Developed original exercise methods incorporating elements of stretching, yoga, and core training, worked with a personal chef and physician to develop a fat-adaptation diet, and more. With a style of examining his body from the inside and outside, he continues to maintain a high level of athletic performance, and has declared his goal to represent Japan in the 2022 World Cup.
About Morinaga Milk’s initiatives with Yuto Nagatomo
Morinaga Milk sensed Yuto Nagatomo’s dedication to constant improvement as a professional athlete, evident in his commitment to physical fitness, diet, and other facets of health within his control. We heard of his concern about his digestive system suffering during extended stays outside Japan despite unflagging self-control, and wanted to apply our findings from many years of research to try to improve his intestinal environment and help him continue to evolve as an athlete from the inside out.
Additionally, “nurturing the next generation” is one of the themes of ESG-focused management, a basic policy from our Medium-Term Business Plan. We aim to teach people the importance of food for maintaining healthy bodies and minds, while also helping them grow as people with positive attributes like agency, autonomy, and motivation to take on challenges, all in an effort to nurture the next generation in order to create a sustainable society.
These goals resonate with Nagatomo, who for his part has established the Yuto Nagatomo Football Academy (YNFA), founded Cuore Inc. with the aim of using his influence as an athlete to solve health problems around the world, and devoted energy to activities in support of single-parent families.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005058/en/
Contact information
Morinaga Milk Industry Co., Ltd.
Investor& Public Relations Department
Ryo Mikami/Mitsunori Watanabe
International Division
Junichi Minami /Chyn Boon Wong
E-mail: interntl-pr@morinagamilk.co.jp
Morinaga Milk website: https://www.morinagamilk.co.jp/english/
Morinaga Probiotics Center website: https://morinagamilk-ingredients.com/
Morinaga Probiotics Center LinkedIn: https://www.linkedin.com/company/morinaga-probiotics-center
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 13:41:00 EEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 11:00:00 EEST | Press release
A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal opportunities across the Group’s production sites and communities. These are just some of the “sustainability” stories the Barilla Group is sharing on World Environment Day with the publication of its 2025 Sustainability Report. The report comes just after Barilla was named the world’s most reputable company in the food sector for the third year running and, for the first time, ranked among the global top 10 in the Global RepTrak 100 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603162436/en/ “The future of the planet will increasingly depend on our ability to spread culture and education,” says Paolo Barilla, Vic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
